```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1              STR
```




```
      G2
 G1 O,S,N
 G2 [@1],[@2],[@3],[@4],[@5],[@6]

Structure attributes must be viewed using STN Express query preparation.
L2              QUE  ABB=ON  PLU=ON  L1


     (FILE 'HOME' ENTERED AT 16:43:14 ON 09 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 16:43:27 ON 09 MAR 2006
L1              STRUCTURE UPLOADED
L2              QUE L1
L3            0 S L2
L4            3 S L2 FUL

     FILE 'CAPLUS' ENTERED AT 16:44:12 ON 09 MAR 2006
L5            1 S L4


COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                5.57     172.72

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -0.75      -0.75

STN INTERNATIONAL LOGOFF AT 16:45:04 ON 09 MAR 2006
```

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:115130 CAPLUS Full-text
DN 134:178474
TI Preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists
IN Kling, Andreas; Geneste, Herve; Lange, Udo; Lauterbach, Arnulf; Graef, Claudia Isabella; Subkowski, Thomas; Holzenkamp, Uta; Mack, Helmut; Sadowski, Jens; Hornberger, Wilfried; Laux, Volker
PA BASF Aktiengesellschaft, Germany
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010847	A2	20010215	WO 2000-EP7440	20000801
	WO 2001010847	A3	20011101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19936780	A1	20010215	DE 1999-19936780	19990809
	CA 2379977	AA	20010215	CA 2000-2379977	20000801
	EP 1202988	A2	20020508	EP 2000-958347	20000801
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000013265	A	20020514	BR 2000-13265	20000801
	TR 200200357	T2	20020923	TR 2002-200200357	20000801
	JP 2003506441	T2	20030218	JP 2001-515313	20000801
	BG 106395	A	20021229	BG 2002-106395	20020206
	NO 2002000644	A	20020318	NO 2002-644	20020208
PRAI	DE 1999-19936780	A	19990809		
	WO 2000-EP7440	W	20000801		

OS MARPAT 134:178474
GI



II

AB RZZ1R1 [I; R = group contg, ≥1 non-H H-bonding atom; R1 = CO2H, or group hydrolizable to CO2H; Z = e.g., (hetero)annelated 2-oxo-1-benzazepin-1,5-diyl; Z1 = bond, (un)substituted NHCH2, -OCH2, -alkylene, -CH:CH, etc.] were prepared Thus, Me 11-methoxycarbonylmethyl-6- oxo-6,11-dihydro-5H-dibenz[b,e]azepine-5-acetate (preparation given) was amidated by N-(2-aminoethyl)pyridine-2-amine to give, after saponification, title compound II. Data for biol. activity of I were given.

IT **326402-02-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists)

RN 326402-02-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-acetic acid, 11-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



IT **326408-68-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists)

RN 326408-68-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-acetic acid, 11-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)